ARS Pharmaceuticals, Inc. Upgraded to Buy: Here's Why
Posted
Zacks (via Benzinga)
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
read more
